Grifols, S.A. (GIFLF)
| Previous Close | 9.41 |
| Open | 9.61 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 9.41 - 9.41 |
| 52 Week Range | 9.41 - 23.69 |
| Volume | |
| Avg. Volume | 900 |
| Market Cap | 5.442B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 94.10 |
| EPS (TTM) | 0.10 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- Reuters
Grifols appoints executive chairman as seeks to speed recovery
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year. Steven F. Mayer, an independent board member since 2011 and a former senior managing director of Cerberus Global Private Equity, will become executive chairman, effective immediately. The company's outgoing non-executive chairman, Victor Grifols Roura, who was chief executive from 1987 to 2016, has been named honorary chairman.
- GlobeNewswire
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi
- CNW Group
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
